What is the 13F Pro Quality Score for VTGN?

13F Pro ranks Vistagen Therapeutics, Inc. (VTGN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VTGN's current score at https://13fpro.ai/company/VTGN (free sign-up required for the full ranking).

Where does 13F Pro source VTGN data?

All Vistagen Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Vistagen Therapeutics, Inc. files with the SEC under CIK 1411685. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VTGN in?

Vistagen Therapeutics, Inc. (VTGN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VTGN research updated on 13F Pro?

VTGN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Vistagen Therapeutics, Inc.(VTGN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1411685 VTGN stock profile & AI dashboard →

13F Pro Quality Score

21.9/100

Rank #2,755 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why VTGN Scores 22/100

exact factor attribution · 2026-09-11

VTGN's composite is driven by revenue growth, held back by free cash flow and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+7.5 pts

88th pct

Institutional flow

-2.1 pts

7th pct

Earnings growth

-2.2 pts

5th pct

Shareholder dilution

-2.3 pts

4th pct

Earnings quality

-3.4 pts

16th pct

Capital efficiency

-4.7 pts

3th pct

Profitability

-6.9 pts

4th pct

Scale

-6.9 pts

4th pct

Free cash flow

-7.0 pts

3th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

VTGN Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Vistagen Therapeutics, Inc. (VTGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VTGN at 21.9/100 on a 32-signal composite quality model, placing it at rank #2,755 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Vistagen Therapeutics, Inc. reports quarterly revenue of $1.5M, net income of $-13.0M. Top institutional holders of VTGN by reported 13-F value include Commodore Capital, VANGUARD CAPITAL MANAGEMENT, TWO SIGMA INVESTMENTS, based on the most recent SEC filings. VTGN trades on the Nasdaq exchange and files with the SEC under CIK 1411685. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VTGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vistagen Therapeutics, Inc. directly from SEC EDGAR. Vistagen Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 8 and 24 since 2022, currently 21.9 — an improving long-term trajectory across 15 quarterly and live scoring snapshots.

✦

Fun facts about Vistagen Therapeutics, Inc.

Quirks, history, and lore behind VTGN — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in California · focused on central nervous system disorders.
2
The Numbers
A micro-cap with minimal revenue — like most clinical-stage biotechs, it runs on cash reserves and capital raises rather than product sales.
3
The History
The company has roots going back to the early 2000s and has spent years developing inhaled and nasal-delivery drug candidates targeting anxiety and other CNS conditions.
4
The Secret
Its lead pipeline targets social anxiety disorder and acute panic attacks using a novel neuroactive steroid approach — a mechanism that has drawn serious attention from the FDA.
5
The Lore
The company's strategy leans heavily on non-intravenous delivery — think a nasal spray instead of an IV drip — to make powerful CNS drugs far more patient-friendly.
6
The Giveaway
Its flagship candidate PH94B (alofisel) targets social anxiety, and the ticker nods to its vision of a new generation of CNS therapies — this is Vistagen.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$1.5M

Net Income

Q2 2026

$-13.0M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+161.1% YoY

$1.3MFY 2026

FY23 $-227.0KFY24 $1.1MFY25 $486.0KFY26 $1.3M

Net Income

-35.5% YoY

$-69.7MFY 2026

FY23 $-59.2MFY24 $-29.4MFY25 $-51.4MFY26 $-69.7M

Operating Income

-28.9% YoY

$-72.1MFY 2026

FY23 $-59.3MFY24 $-33.0MFY25 $-56.0MFY26 $-72.1M

EPS (Diluted)

-9.6% YoY

$-1.83FY 2026

FY23 $-8.51FY24 $-1.52FY25 $-1.67FY26 $-1.83

Total Assets

-42.4% YoY

$48.6MFY 2026

FY23 $21.1MFY24 $123.7MFY25 $84.3MFY26 $48.6M

Op. Cash Flow

-57.8% YoY

$-66.4MFY 2026

FY23 $-49.7MFY24 $-25.8MFY25 $-42.1MFY26 $-66.4M

Free Cash Flow

—FY 2026

FY23 $-50.2MFY24 $-25.8MFY25 —FY26 —

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$1.3M +161.1%	$486.0K -54.3%	$1.1M +568.7%	$-227.0K -120.5%	$1.1M +1.8%	$1.1M
Net Income	$-69.7M -35.5%	$-51.4M -75.1%	$-29.4M +50.4%	$-59.2M -24.0%	$-47.8M -166.3%	$-17.9M
Operating Income	$-72.1M -28.9%	$-56.0M -69.5%	$-33.0M +44.3%	$-59.3M -24.0%	$-47.8M -166.4%	$-17.9M
EPS (Diluted)	$-1.83 -9.6%	$-1.67 -9.9%	$-1.52 +82.1%	$-8.51	—	—
Total Assets	$48.6M -42.4%	$84.3M -31.8%	$123.7M +486.3%	$21.1M -71.7%	$74.6M -31.1%	$108.3M
Operating Cash Flow	$-66.4M -57.8%	$-42.1M -63.1%	$-25.8M +48.1%	$-49.7M -9.9%	$-45.3M -274.8%	$-12.1M
Free Cash Flow	—	—	$-25.8M +48.6%	$-50.2M -11.0%	$-45.3M -266.5%	$-12.3M

Get alerted when VTGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Vistagen Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VTGN

Commodore Capital LP
$630.2K2,788,620 sh
VANGUARD CAPITAL MANAGEMENT LLC
$355.8K1,574,200 sh
TWO SIGMA INVESTMENTS, LP
$191.6K847,992 sh
ACADIAN ASSET MANAGEMENT LLC
$178.0K794,579 sh
RENAISSANCE TECHNOLOGIES LLC
$165.1K730,500 sh
Ikarian Capital, LLC
$117.3K519,077 sh
AdvisorShares Investments LLC
$99.1K438,643 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$95.5K415,400 sh
LUMINUS MANAGEMENT LLC
$91.1K403,115 sh
GEODE CAPITAL MANAGEMENT, LLC
$82.5K365,002 sh

Fund	Value	Shares
Commodore Capital LP	$630.2K	2,788,620
VANGUARD CAPITAL MANAGEMENT LLC	$355.8K	1,574,200
TWO SIGMA INVESTMENTS, LP	$191.6K	847,992
ACADIAN ASSET MANAGEMENT LLC	$178.0K	794,579
RENAISSANCE TECHNOLOGIES LLC	$165.1K	730,500
Ikarian Capital, LLC	$117.3K	519,077
AdvisorShares Investments LLC	$99.1K	438,643
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$95.5K	415,400
LUMINUS MANAGEMENT LLC	$91.1K	403,115
GEODE CAPITAL MANAGEMENT, LLC	$82.5K	365,002

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VTGN on your watchlist

Track score changes the day Vistagen Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VTGN a good stock to buy?

13F Pro's AI-powered analysis of Vistagen Therapeutics, Inc. (VTGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VTGN are available on the VTGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VTGN is classified as a small company.

Which hedge funds own VTGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VTGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vistagen Therapeutics, Inc.'s investment landscape.